Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | Director | July 15, 2022 | July 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date July 15, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,597 |
Ending reported balance
After 2022-07-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-15 · Exercise / conversion · Acquired 5,333 · Balance 56,932 F1: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. Row 2 · 2022-07-15 · Exercise / conversion · Acquired 2,665 · Balance 59,597 F2: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 9,775 |
Reported balance
After 2022-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-15 · Exercise / conversion · Disposed 5,333 · Balance 9,775 F3: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,110 |
Reported balance
After 2022-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-15 · Exercise / conversion · Disposed 2,665 · Balance 7,110 F3: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company. |
| Common StockSEC Table I · non-derivative | IndirectBy Cooley Pen Plan | 1,500 |
Reported balance
Holding disclosure · report date 2022-07-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
F2: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
F3: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.
F5: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2019 Filed Jun 6, 2019 22:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 15,000 | $65.29 | $979,350.00 |
DisclosureSEC source: 0000874015-19-000070 · edgar.xml · nonDerivative · entry 2 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,794 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.05 to $65.50, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:35 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 15,000 | $16.32 | $244,800.00 |
DisclosureSEC source: 0000874015-19-000070 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. Read SEC document |
| May 06, 2019 Filed May 8, 2019 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $24.42 | $0.00 |
DisclosureSEC source: 0000874015-19-000065 · edgar.xml · derivative · entry 4 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed May 8, 2019 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 8,000 | $72.75 | $582,001.60 |
DisclosureSEC source: 0000874015-19-000065 · edgar.xml · nonDerivative · entry 2 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,794 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.60 to $72.92, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 06, 2019 Filed May 8, 2019 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 8,000 | $24.42 | $195,360.00 |
DisclosureSEC source: 0000874015-19-000065 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 4/4/2019. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 19:11 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000081 · edgar.xml · derivative · entry 5 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 19:11 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000081 · edgar.xml · nonDerivative · entry 2 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:11 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantDirector Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $42.88 | $0.00 |
DisclosureSEC source: 0000874015-18-000081 · edgar.xml · derivative · entry 7 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-07-01 F5 · derivative.exercise_date: Grant of July 2, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 2, 2019. The option shall be fully vested and exercisable on July 2, 2022. The option is exercisable to 0 shares on July 2, 2018. F5 · derivative.expiration_date: Grant of July 2, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 2, 2019. The option shall be fully vested and exercisable on July 2, 2022. The option is exercisable to 0 shares on July 2, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:11 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 3,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000081 · edgar.xml · derivative · entry 6 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,555 Underlying: Common Stock · 3,555 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 2, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 2, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2022. The RSU is vested as to 0 shares on July 2, 2018. F4 · derivative.expiration_date: Grant of July 2, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 2, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 2, 2022. The RSU is vested as to 0 shares on July 2, 2018. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:11 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000081 · edgar.xml · derivative · entry 4 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,999 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 19:11 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000081 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 00:02 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Employee Director Stock Option · Derivative | 15,000 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0000874015-18-000067 · edgar.xml · derivative · entry 4 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 00:02 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 15,000 | $46.45 | $696,750.00 |
DisclosureSEC source: 0000874015-18-000067 · edgar.xml · nonDerivative · entry 2 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $46.60, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 00:02 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 15,000 | $13.88 | $208,200.00 |
DisclosureSEC source: 0000874015-18-000067 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantDirector Stock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $52.22 | $0.00 |
DisclosureSEC source: 0000874015-17-000040 · edgar.xml · derivative · entry 5 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2027-07-02 F5 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017. F5 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on July 3, 2018. The option shall be fully vested and exercisable on July 3, 2021. The stock option was exercisable as to 0 shares on July 3, 2017. Read SEC document |
| July 03, 2017 Filed Jul 3, 2017 21:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Units · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000040 · edgar.xml · derivative · entry 4 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 2,667 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017. F4 · derivative.expiration_date: Grant of July 3, 2017 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on July 3, 2018. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 3, 2021. The RSU is vested as to 0 shares on July 3, 2017. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Units · Derivative | 2,469 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000040 · edgar.xml · derivative · entry 3 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,999 Underlying: Common Stock · 2,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| July 01, 2017 Filed Jul 3, 2017 21:33 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 2,469 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-17-000040 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Employee Director Stock Option · Derivative | 12,500 | $0.00 Strike: $9.77 | $0.00 |
DisclosureSEC source: 0000874015-17-000035 · edgar.xml · derivative · entry 4 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2017-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 12,500 | $45.22 | $565,250.00 |
DisclosureSEC source: 0000874015-17-000035 · edgar.xml · nonDerivative · entry 2 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,658 F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 7/1/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 7/1/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.40, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 22:16 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,500 | $9.77 | $122,125.00 |
DisclosureSEC source: 0000874015-17-000035 · edgar.xml · nonDerivative · entry 1 MUTO FREDERICK T · CIK 0001181560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option that was scheduled to expire on 7/1/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 7/1/2017. The purchase and sale reported on this Form 4 was effective pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 6/26/2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.